|
[1] WALDENSTROM J. Liver,blood proteins and nutritive protein[J]. Dtsch Z Verdau Stoffwechselkr,1953,9:113-119.
|
|
[2] JOHNSON PJ,MCFARLANE IG. Meeting report:International Autoimmune Hepatitis Group[J]. Hepatology,1993,18(4):998-1005.
|
|
[3] ROBERTS SK,KEMP W. Salvage therapies for autoimmune hepatitis:A critical review[J]. Semin Liver Dis,2017,37(4):343-362.
|
|
[4] European Association for the Study of the Liver. EASL clinical practice guidelines:Autoimmune hepatitis[J]. J Hepatol,2015,63(4):971-1004.
|
|
[5] SHI JJ,TAN YW. Meta-analysis of the efficacy and safety of budesonide and prednisone in combination with azathioprine respectively in the treatment of autoimmune hepatitis[J/CD].Chin J Liver Dis(Electronic Version),2019,11(3):36-41.(in Chinese)史浚颉，谭友文．布地奈德与泼尼松分别联合硫唑嘌呤治疗自身免疫性肝炎疗效与安全性的Meta分析[J/CD]．中国肝脏病杂志(电子版)，2019,11(3):36-41.
|
|
[6] ZIZZO AN,VALENTINO PL,SHAH PS,et al. Second-line agents in pediatric patients with autoimmune hepatitis:A systematic review and meta-analysis[J]. J Pediatr Gastroenterol Nutr,2017,65(1):6-15.
|
|
[7] DANIELSSON A,PRYTZ H. Oral budesonide for treatment of autoimmune chronic active hepatitis[J]. Aliment Pharmacol Ther,1994,8(6):585-590.
|
|
[8] FERNANDES NF,REDEKER AG,VIERLING JM,et al. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis[J]. Am J Gastroenterol,1999,94(1):241-248.
|
|
[9] CZAJA AJ,LINDOR KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis[J]. Gastroenterology,2000,119(5):1312-1316.
|
|
[10] RICHARDSON PD,JAMES PD,RYDER SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine[J]. J Hepatol,2000,33(3):371-375.
|
|
[11] MALEKZADEH R,NASSERI-MOGHADDAM S,KAVIANI MJ,et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis[J]. Dig Dis Sci,2001,46(6):1321-1327.
|
|
[12] AQEL BA,MACHICAO V,ROSSER B,et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis[J]. J Clin Gastroenterol,2004,38(9):805-809.
|
|
[13] DEVLIN SM,SWAIN MG,URBANSKI SJ,et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy[J]. Can J Gastroenterol,2004,18(5):321-326.
|
|
[14] CZAJA AJ,CARPENTER HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil:Comparison with conventional treatment for refractory disease[J]. J Clin Gastroenterol,2005,39(9):819-825.
|
|
[15] CHATUR N,RAMJI A,BAIN VG,et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis:The Canadian association for the study of liver(CASL)experience with mycophenolate mofetil and tacrolimus[J]. Liver Int,2005,25(4):723-727.
|
|
[16] CSEPREGI A,RCKEN C,TREIBER G,et al. Budesonide induces complete remission in autoimmune hepatitis[J]. World J Gastroenterol,2006,12(9):1362-1366.
|
|
[17] INDUCTIVO-YU I,ADAMS A,GISH RG,et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy[J]. Clin Gastroenterol Hepatol,2007,5(7):799-802.
|
|
[18] HLIVKO JT,SHIFFMAN ML,STRAVITZ RT,et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2008,6(9):1036-1040.
|
|
[19] HENNES EM,OO YH,SCHRAMM C,et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?[J].Am J Gastroenterol,2008,103(12):3063-3070.
|
|
[20] ZANDIEH I,KRYGIER D,WONG V,et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada[J].Can J Gastroenterol,2008,22(4):388-392.
|
|
[21] SHARZEHI K,HUANG MA,SCHREIBMAN IR,et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy[J].Can J Gastroenterol,2010,24(10):588-592.
|
|
[22] EFE C,HAGSTRM H,YTTING H,et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2017,15(12):1950-1956.
|
|
[23] PEISELER M,LIEBSCHER T,SEBODE M,et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol,2018,16(2):260-267.
|
|
[24] ROBERTS SK,LIM R,STRASSER S,et al. Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy[J]. Clin Gastroenterol Hepatol,2018,16(2):268-277.
|
|
[25] HUANG ZJ,XU ZJ,ZENG CP. Clinical efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis[J].Hainan Med J,2013,24(21):3143-3145.(in Chinese)黄志杰，许正锯，曾翠萍．他克莫司治疗类固醇抗性自身免疫性肝炎的临床疗效分析[J]．海南医学，2013,24(21):3143-3145.
|
|
[26] BAVEN-PRONK AM,COENRAAD MJ,van BUUREN HR,et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes[J]. Aliment Pharmacol Ther,2011,34(3):335-343.
|
|
[27] GIANNAKOPOULOS G,VERBAAN H,FRIIS-LIBY IL,et al.Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine[J]. Dig Liver Dis,2019,51(2):253-257.
|
|
[28] PAPE S,NEVENS F,VERSLYPE C,et al. Profiling the patient with autoimmune hepatitis on calcineurin inhibitors:A realworld-experience[J]. Eur J Gastroenterol Hepatol,2020,32(6):727-732.
|
|
[29] EFE C,TAII HA,YTTING H,et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis[J]. Dig Dis Sci,2018,63(5):1348-1354.
|
DownLoad: